Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy Extension Study of Afimkibart in Atopic Dermatitis
2025-520771-59-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2 trial of afimkibart in atopic dermatitis (AD) (2 arms), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Planned start Feb 2026; status: authorised.
02
Drugs
afimkibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-520771-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520771-59-00.